KemPharm, Inc. (KMPH) Stock Rating Upgraded by Zacks Investment Research

KemPharm, Inc. (NASDAQ:KMPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm currently has a $4.25 price target on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 14.86% from the company’s previous close.

According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

A number of other analysts also recently weighed in on KMPH. Canaccord Genuity set a $7.00 price target on KemPharm and gave the stock a “buy” rating in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. set a $13.00 price target on KemPharm and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. KemPharm currently has an average rating of “Buy” and an average target price of $8.05.

Shares of KemPharm (NASDAQ KMPH) opened at $3.70 on Wednesday. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. KemPharm has a 1-year low of $2.45 and a 1-year high of $5.40.

ILLEGAL ACTIVITY WARNING: “KemPharm, Inc. (KMPH) Stock Rating Upgraded by Zacks Investment Research” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/15/kempharm-inc-kmph-stock-rating-upgraded-by-zacks-investment-research.html.

In other news, major shareholder Delaware Street Capital Master bought 325,888 shares of KemPharm stock in a transaction dated Thursday, September 14th. The stock was bought at an average cost of $3.27 per share, for a total transaction of $1,065,653.76. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders bought 335,188 shares of company stock valued at $1,090,088. 25.40% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of KMPH. Bank of New York Mellon Corp grew its stake in shares of KemPharm by 17.6% in the 1st quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares during the period. C WorldWide Group Holding A S boosted its stake in KemPharm by 110.1% during the 2nd quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in KemPharm by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after purchasing an additional 17,721 shares during the last quarter. Institutional investors own 39.36% of the company’s stock.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply